Basel/Switzerland, 15 August 2008

Speedel Holding Ltd. (SWX: SPPN) today announced the outcome of theExtraordinary General Meeting (EGM) of the shareholders of Speedelwhich took place yesterday at the Hilton Hotel, Basel, Switzerland.Key agenda item was the election of new members to the Board ofDirectors.

Together with the invitation, the Board of Directors of Speedel hadrecommended the following persons to be elected for a three yearsterm:

  * Dr. Raymund Breu - Chief Financial Officer, Novartis    International  * Joseph Jimenez - Chief Executive Officer, Novartis Pharma  * Jonathan Peacock - Chief Financial Officer, Novartis Pharma  * Joerg Walther - Global Head, Legal M&A and Antitrust, Novartis    International

The proposal of the Board was approved by the shareholders with astrong majority.

After the closing of the EGM the new Board of Directors of Speedelmet for its constituent meeting and elected Joseph Jimenez asChairman and Dr. Fritz Kunz as Vice Chairman. Additionally the newBoard decided upon Dr. Andrin Oswald as the new CEO of Speedel.

Dr. Fritz Kunz, Vice Chairman of the Board, commented: "We welcomethe new members of the Board and the new CEO. They will lead Speedelthrough the period of integration."

The Slides presented at the EGM can be accessed on the company'swebsite athttp://www.speedel.com/section/6/subsections/8.

About Speedel

Speedel is a public biopharmaceutical company that seeks to createvalue for patients, partners and investors by developing innovativetherapies for cardiovascular and metabolic diseases. Speedel is aworld leader in renin inhibition, a promising new approach withsignificant potential for treating cardiovascular diseases. Our leadcompound SPP100, Aliskiren (Rasilez/Tekturna[1]) the first-in-classdirect renin inhibitor, was in-licensed from Novartis in 1999 andlicensed-back to Novartis Pharma in 2002 for further development andcommercialisation; SPP100 was approved by the FDA in the US in March2007, and by the EMEA in the EU in August 2007. Our pipeline coversfour different modes of action, and in addition to SPP100, includesSPP301 (an endothelin receptor A antagonist) in Phase II, SPP200 (adirect thrombin inhibitor) in Phase II, the next generation renininhibitors SPP635 (in Phase Il), SPP1148 and SPP676 (both in Phase I)and several pre-clinical projects, including SPP2745 (aldosteronesynthase inhibitor).Speedel develops novel product candidates through focused innovationand smart drug development from lead identification to the end ofPhase II. We either partner with big pharma for Phase III andcommercialisation in primary-care indications, or we may ourselvescomplete Phase III development in specialist indications. Candidatecompounds for development and the company's intellectual propertycome from our late-stage research unit Speedel Experimenta and fromin-licensing. Our team of approximately 80 employees, including over30 experienced pharmaceutical scientists, is located at ourheadquarters and laboratories in Basel, Switzerland and at offices inNew Jersey, USA and Tokyo, Japan.Speedel was founded in 1998 as a private company. In September 2005the company's shares were listed on the SWX Swiss Exchange under thesymbol SPPN. Further information is available at www.speedel.com.

Forward looking statements

This press release includes forward-looking statements that involvesubstantial risks and uncertainties. These forward-looking statementsare based on our current expectations and projections about futureevents. All statements, other than statements of historical facts,regarding our strategy, future operations, future financial position,future revenues, projected costs, prospects, plans and objectives ofmanagement are forward-looking statements. The word "may" and similarexpressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifyingwords. We may not actually achieve the plans, intentions orexpectations described in these forward-looking statements and youshould not place undue reliance on them. There can be no assurancethat actual results of our research and development activities andour results of operations will not differ materially from theseexpectations. Factors that could cause actual results to differ fromexpectations include, among others: our or our partners' ability todevelop safe and efficacious products; our or our partners' abilityto achieve positive results in clinical trials; our or our partners'ability to obtain marketing approval and market acceptance for ourproduct candidates; our ability to enter into future collaborationand licensing agreements; the impact of competition and technologicalchange; existing and future regulations affecting our business;changes in governmental oversight of pharmaceutical productdevelopment; the future scope of our patent coverage or that of thirdparties; the effects of any future litigation; general economic andbusiness conditions, both internationally and within our industry,including exchange rate variations; and our future financing plans.

-- Ends --

[1] Rasilez/Tekturna® are Novartis trademarks.

For further information please contact:Dr. Harald F. SchaeferDirector Communications & Investor RelationsSpeedelHirschgässlein 11CH - 4051 BaselSwitzerlandT +41 (0) 61 206 40 00D +41 (0) 61 206 40 14F +41 (0) 61 206 40 01M +41 (0) 79 629 76 71E harald.schaefer@speedel.comwww.speedel.com

Copyright © Hugin AS 2008. All rights reserved.